- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NewAmsterdam Pharma Company NV (NAMS)
NewAmsterdam Pharma Company NV stock price live, this page displays NASDAQ NAMS stock exchange data. View the NAMS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the NewAmsterdam Pharma Company NV real time stock price chart below.
What Is the NewAmsterdam Pharma Company NV Stock Price Today?
The NewAmsterdam Pharma Company NV stock price today is 34.010.
What Is the Stock Symbol for NewAmsterdam Pharma Company NV?
The stock ticker symbol for NewAmsterdam Pharma Company NV is NAMS.
Is NAMS the Same as $NAMS?
$NAMS is a common way to refer to the NewAmsterdam Pharma Company NV ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does NewAmsterdam Pharma Company NV Trade On?
NewAmsterdam Pharma Company NV is listed and trades on the NASDAQ stock exchange.
Is NewAmsterdam Pharma Company NV a Good Stock to Buy?
Determining whether NewAmsterdam Pharma Company NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current NewAmsterdam Pharma Company NV share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAMS quote. (ISIN: NL00150012L7)
What Is the NewAmsterdam Pharma Company NV Stock Price Today?
The NewAmsterdam Pharma Company NV stock price today is 34.010.
What Is the Stock Symbol for NewAmsterdam Pharma Company NV?
The stock ticker symbol for NewAmsterdam Pharma Company NV is NAMS.
Is NAMS the Same as $NAMS?
$NAMS is a common way to refer to the NewAmsterdam Pharma Company NV ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does NewAmsterdam Pharma Company NV Trade On?
NewAmsterdam Pharma Company NV is listed and trades on the NASDAQ stock exchange.
Is NewAmsterdam Pharma Company NV a Good Stock to Buy?
Determining whether NewAmsterdam Pharma Company NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current NewAmsterdam Pharma Company NV share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAMS quote. (ISIN: NL00150012L7)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.260
34.750
52 wk Range
15.820
42.000
NAMS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.26034.750
52 wk Range
15.82042.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NAMS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
49.921
Upside
+46.78%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company NV SWOT Analysis
Investment Outlook | With analyst price targets ranging from $38 to $48, NewAmsterdam Pharma's financial health and market potential present an intriguing investment case in cardiovascular therapeutics. |
Market Projections | Analysts forecast peak worldwide sales of $4.3 billion, with U.S. sales potentially reaching $2.7 billion, highlighting obicetrapib's significant market opportunity. |
Trial Triumphs | Explore the impressive BROADWAY trial results and the ongoing PREVAIL study, which could cement obicetrapib's position in the competitive lipid-lowering market. |
Cardiovascular Pionee | NewAmsterdam Pharma's obicetrapib shows promise in cholesterol reduction, potentially revolutionizing cardiovascular disease treatment as a second-line therapy. |
Compare NAMS to Peers and Sector
Metrics to compare | NAMS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNAMSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.2x | −12.4x | −0.5x | |
PEG Ratio | −0.59 | −0.24 | 0.00 | |
Price / Book | 5.7x | 5.1x | 2.6x | |
Price / LTM Sales | 173.8x | 8.9x | 3.2x | |
Upside (Analyst Target) | 43.1% | 54.4% | 45.7% | |
Fair Value Upside | Unlock | −5.1% | 4.8% | Unlock |
Analyst Ratings
14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 49.921
(+46.78% Upside)
Earnings
Latest Release
Feb 18, 2026
EPS / Forecast
-0.63 / -0.40
Revenue / Forecast
32K / 2.88M
People Also Watch
FAQ
What Is the NewAmsterdam Pharma (NAMS) Stock Price Today?
The NewAmsterdam Pharma stock price today is 34.010 USD.
What Stock Exchange Does NewAmsterdam Pharma Trade On?
NewAmsterdam Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for NewAmsterdam Pharma?
The stock symbol for NewAmsterdam Pharma is "NAMS."
What Is the NewAmsterdam Pharma Market Cap?
As of today, NewAmsterdam Pharma market cap is 3.900B USD.
What Is NewAmsterdam Pharma's Earnings Per Share (TTM)?
The NewAmsterdam Pharma EPS (TTM) is -1.721.
When Is the Next NewAmsterdam Pharma Earnings Date?
NewAmsterdam Pharma will release its next earnings report on May 07, 2026.
From a Technical Analysis Perspective, Is NAMS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has NewAmsterdam Pharma Stock Split?
NewAmsterdam Pharma has split 0 times.
How Many Employees Does NewAmsterdam Pharma Have?
NewAmsterdam Pharma has 100 employees.
What is the current trading status of NewAmsterdam Pharma (NAMS)?
As of Apr 16, 2026, NewAmsterdam Pharma (NAMS) is trading at a price of 34.010 USD, with a previous close of 34.440 USD. The stock has fluctuated within a day range of 33.260 USD to 34.750 USD, while its 52-week range spans from 15.820 USD to 42.000 USD.
What Is NewAmsterdam Pharma (NAMS) Price Target According to Analysts?
The average 12-month price target for NewAmsterdam Pharma is 49.921 USD, with a high estimate of 61.63462672 USD and a low estimate of 38.08939733 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +46.78% Upside potential.
What Is the NAMS Premarket Price?
NAMS's last pre-market stock price is 33.400 USD. The pre-market share volume is 4,830.000, and the stock has decreased by -1.040, or -3.020%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.